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Hepatitis C virus (HCV) infection has a strong tendency to evolve to chronicity despite up-
regulation of proapoptotic cytokines in the inﬂamed liver. The mechanisms responsible for
persistent viral replication in this inﬂammatory environment are obscure. It is conceivable that
viralreplicationwouldbefacilitatediftheinfectedhepatocytesarerenderedresistanttocytokine-
induced cytotoxicity. In this study, we investigated if an adenovirus encoding HCV core and E1
(RAdCE1) could reduce liver cell injury in different in vivo models of cytokine-mediated hepa-
totoxicity in mice. We show that RAdCE1 markedly attenuates hepatocellular apoptosis and the
increase in serum transaminase levels after concanavalin A (con A) challenge. This protective
effect is accompanied by an inhibition of nuclear translocation of nuclear factor B (NF-B);
reducedexpressionofinduciblenitricoxidesynthase(iNOS);decreasedhepaticmessengerRNA
levels of chemokines macrophage inﬂammatory protein 2 (MIP-2), monocyte chemoattractant
protein 1 (MCP-1), and interferon-inducible protein 10 (IP-10); and abrogation of liver leuko-
cyte inﬁltration. RAdCE1 also causes a reduction in serum transaminase levels and inhibits
hepatocellular apoptosis in mice given tumor necrosis factor (TNF)- plus D-galactosamine. In
conclusion, HCV structural antigens can protect liver cells against the proapoptotic effects of
proinﬂammatory cytokines. The antiapoptotic status of infected liver cells may represent a mecha-
nism favoring viral persistence. Our ﬁndings also suggest that, in chronic hepatitis C, the burden of
hepatocellular damage mainly affects noninfected liver cells. (HEPATOLOGY 2003;37:461-470.)
H
epatitis C virus (HCV) is a single-stranded
RNA virus1 characterized by its ability to cause
persistent infection and chronic hepatitis.
Chronic HCV infection constitutes a major health prob-
lem in both western and developing worlds because of its
high prevalence and the propensity of chronic hepatitis C
toevolvetolivercirrhosisandeventuallytohepatocellular
carcinoma.2 Persisting infection is facilitated by a diver-
sity of mechanisms that allow the virus to escape host
adaptive immunity.3-5
In most patients with chronic HCV infection, there is
an active inﬂammatory reaction in the liver with up-reg-
ulation of proinﬂammatory cytokines, notably tumor ne-
crosis factor (TNF)- and interferon (IFN)-,6,7 which
display both cytotoxic and antiviral effects. This process
contributes to the hepatocellular injury seen in most
HCV-infected patients but does not prevent HCV repli-
cation in liver cells. Mechanisms that make the cytokine
response inefﬁcient in controlling the infection have not
been elucidated.
The 9.6-kilobase genome of HCV contains highly
conserved untranslated regions at both 5 and 3 termini,
which ﬂank a large open reading frame encoding for 3
structural (core, E1, and E2) and at least 6 nonstructural
(NS2, NS3, NS4a, NS4b, NS5a, and NS5b) proteins.8
Although extensive study of the HCV genome has shown
thecontributionoftranslatedviralproteinstothevirallife
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461cycle, the effect of HCV proteins on the functions of
infectedcellsisrelativelyunknown.Previousinvitrostud-
ies have shown that HCV proteins affect many signal
pathways.Amongthem,HCVcoreandNS4Bseemtobe
the most active at interfering cell signaling,9 but the in
vivo consequences of the interactions between viral and
cellular proteins have not yet been analyzed. It has been
reported that HCV core protein binds to the cytoplasmic
domainofcertainmembersoftheTNF-receptorsuper-
family, modulating the sensitivity of infected cells to the
stimulus provided by their respective ligands.10-13 How-
ever, based on in vitro data, there is controversy with
respect to the role of HCV core protein on the TNF-
receptor superfamily signaling pathways. Thus, it has
been reported that core protein activates10,12,13 or inhib-
its9,14,15 TNF-–induced apoptosis. Similarly, there are
contradictoryreportsregardingtheroleofHCVcorepro-
tein on TNF-–induced nuclear factor B( N F - B) ac-
tivation, and it has been reported that HCV core protein
inhibits,10,12,16 has no effect,17 or even activates9,15,18 NF-
B. It is likely that these discrepancies may be related to
differences in the cell lines used and/or differences in cul-
ture conditions.
In this study, we investigated whether transduction of
the mouse liver with an adenovirus encoding HCV core
and E1 (RAdCE1) proteins could protect liver cells from
cytokine-induced hepatocellular damage in 2 experimen-
tal models of TNF-–mediated hepatic injury. Our re-
sults show that RAdCE1 strongly reduces liver cell death
in mice challenged with concanavalin A (con A) or with
TNF- plus D-galactosamine, suggesting that HCV-in-
fected cells might resist the apoptotic effect of cytokines,
becoming a privileged site for continuing viral replication
within an inﬂammatory environment.
Materials and Methods
Mice. Six-week-old female BALB/c mice were pur-
chased from IFFA Credo (Barcelona, Spain). The mice
were hosted in appropriate animal care facilities and han-
dled following institutional guidelines required for exper-
imentation with animals.
Recombinant Adenoviruses. Recombinant adenovi-
ruses RAdCE1, expressing HCV core and E1 proteins,
and RAdLacZ, expressing -galactosidase, have been pre-
viouslydescribed.19Viruseswerepropagatedon293cells,
puriﬁed in a CsCl isopyknic banding step, and kept in
aliquots at 80°C.
Induction of Acute Liver Injury. Acute liver injury
was induced by intravenous administration of 100 mg/kg
con A (Sigma Chemical Co., St. Louis, MO) in 250 L
saline via the tail vein or by intravenous administration of
0.5 g TNF-/mouse (Peprotech, London, England)
plus intraperitoneal administration of 25 mg D-galac-
tosamine/mouse(SigmaChemicalCo.)(TNF-/D-galac-
tosamine). Six hours after administration of con A or
TNF-/D-galactosamine, mice were bled for biochemical
analyses and killed for histopathologic studies. Livers sec-
tions were stored in different conditions: (1) ﬁxed in for-
mol for parafﬁn inclusion, (2) frozen in OCT for
immunohistochemical analysis, and (3) frozen in liquid
nitrogen for RNA or protein isolation.
Liver Function Tests and Cytokines. Liver injury
was estimated by determining the serum levels of alanine
aminotransferase using a colorimetric method based on
the capacity of 2,4-dinitrophenylhydrazine to react with
pyruvate (Sigma Chemical Co.). Alanine aminotransfer-
ase values were expressed as Sigma-Frankel units per mil-
liliter. Determination of total bilirubin in serum was
performed in the presence of dimethyl sulfoxide by diazo
reactionwithdiazotizedsulfanilicacid(ABXDiagnostics,
Montpelier, France). Serum concentration of IFN- and
TNF- was measured using commercially available en-
zyme-linked immunosorbent assays (BD Biosciences
Pharmingen, San Diego, CA) according to the manufac-
turer’s instructions.
Measurement of Apoptosis. Apoptosis was measured
inliversectionsbyusingtheInSituCellDeathDetection
Kit, POD (Boehringer Mannheim, Mannheim, Ger-
many) according to the manufacturer’s instructions.
Brieﬂy, tissue sections were ﬁxed with 4% paraformalde-
hyde, endogenous peroxidase blocked (0.3% H2O2 in
methanol), and permeabilized by incubation with a solu-
tion containing 0.1% Triton X-100. Samples were la-
beled with ﬂuoresceinated nucleotides by terminal
deoxynucleotidyl transferase. Apoptosis was observed un-
der ﬂuorescence microscopy.
Isolation of Liver Nuclear Extracts and Determi-
nation of Active NF-B by Electrophoretic Mobility
Shift Assay Analysis. Liver nuclear extracts were ob-
tained as previously described.20 Supernatants containing
the protein nuclear extracts were collected and stored at
80°C. One small aliquot of nuclear extracts was used to
determine protein concentration with the Bradford re-
agent (Bradford Bio-Rad protein assay; Bio-Rad, Her-
cules, CA). NF-B binding activity was determined by
electrophoreticmobilityshiftassaywithacommercialoli-
gonucleotide containing the B consensus site (Promega,
Madison, WI) labeled with [-32P]–adenosine triphos-
phate as previously described20 and using 5 g of liver
nuclear extracts. For competition experiments, a molar
excessoftheunlabeledBoligonucleotidewasaddedand
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labeled probe (not shown).
Ribonuclease Protection Assays. Liver tissue sections
were processed for total RNA isolation by liver homoge-
nization in 1 mL Ultraspect (Biotex, Houston, TX) with
an Ultraturrax Driver T.25 (Janke & Kunkel, Ika-
Labortechnik, Staufen, Germany). Total RNA was iso-
lated following the manufacturer’s instructions. The
multiprobe ribonuclease protection assay (Riboquant;
BDBiosciencesPharmingen)wasperformedaccordingto
the manufacturer’s instructions using the multiprobe
template set mCK-5b or speciﬁc probes for interferon-
inducible protein 10 (IP-10) and for glyceraldehyde-3-
phosphate dehydrogenase.
Immunostainings. Liver tissue was embedded in Tis-
sue Tek compound (Miles Laboratories, Inc., Naperville,
IL) and immediately frozen in liquid nitrogen. Tissue
sections were ﬁxed with 4% paraformaldehyde, endoge-
nous peroxidase blocked (0.3% H2O2 in methanol), and
permeabilized by incubation with a solution containing
0.1% Triton X-100. Samples were examined by indirect
immunoperoxidase technique using an anti-core mono-
clonal antibody (kindly provided by Dr. Martinez-Anso,
University of Navarra, Pamplona, Spain).
The identity of HCV core–expressing cells and apo-
ptotic cells was analyzed by double staining using termi-
nal deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) reaction (green
ﬂuorescence)andindirectimmunostainingwithanti-core
speciﬁc antibodies and anti–immunoglobulin G/Cy3
(Jackson ImmunoResearch, West Grove, PA) (red ﬂuo-
rescence). After performing the anti-core speciﬁc immu-
nostaining, we performed TUNEL reaction as previously
described. Analysis of double-labeling experiments was
performed under a ﬂuorescence microscope using differ-
ent ﬁlters.
Western Blot Analysis. Liver pieces were homoge-
nized in lysis buffer (1 mmol/L ethylenediaminetetraace-
tic acid, 1 mmol/L NaF, 20 mmol/L Tris-HCl, 150
mmol/LNaCl,1%TritonX-100,1mmol/Lsodiumvan-
adate, 1 mmol/L phenylmethylsulfonyl ﬂuoride, 1
g/mL pepstatin, 0.5 g/mL aprotinin, and 3 g/mL
leupeptin) using a glass-Teﬂon homogenizer. Extracts
were cleared by centrifugation at 75,000 rpm at 4°C for
45 minutes. Twenty-ﬁve micrograms of protein from
each sample was loaded onto 8% sodium dodecyl sulfate
acrylamide gels followed by electrophoretic transfer to
nitrocellulosemembranes.Induciblenitricoxidesynthase
(iNOS) was detected using rabbit polyclonal anti-iNOS
antibody (Santa Cruz Biotechnology, Santa Cruz, CA)
and secondary anti-rabbit horseradish peroxidase–conju-
gated antibody (Santa Cruz Biotechnology). Incubation
ofmembraneswithmouseimmunoglobulinMmonoclo-
nal anti-actin antibody (Ab-1) followed by incubation
with horseradish peroxidase–conjugated anti-mouse im-
munoglobulin M secondary antibody (Calbiochem,
Darmstadt, Germany) was used for internal control. Pro-
tein bands were detected by enhanced chemiluminescence
(Amersham Pharmacia Biotech, Freiburg, Germany).
Results
Injection of Recombinant Adenovirus Expressing
HCV Core and E1 Proteins Protects Mice From con
A–Induced Acute Severe Hepatitis. Adenoviral vectors
have strong hepatotropism. Doses of 109 plaque-forming
units (pfu) RAdLacZ given intravenously resulted in
transduction of more than 60% of liver cells with few
occasional positive cells in other organs such as the kid-
neys,lungs,andspleen,whereas107pfuinfectedlessthan
10% of hepatocytes (data not shown). After intravenous
administration of 109 pfu RAdCE1, HCV core protein
couldbedetectedbyanindirectimmunoperoxidasetech-
nique in more than 60% of liver cells, showing a diffuse
cytoplasmic staining of hepatocytes and a more intense
staining of nonparenchymal cells (Fig. 1A and B). As
Fig. 1. Expression of HCV core in liver tissue of mice injected with
RAdCE1 or RAdLacZ and protection against con A–induced liver damage
in animals treated with RAdCE1. Indirect immunoperoxidase staining of
HCV core protein in liver sections from mice injected intravenously with
1  109 pfu (A) RAdCE1 or (B) RAdLacZ. (Original magniﬁcation 200.)
(C) Groups of 4 mice were injected intravenously with different doses of
RAdCE1, 1  109 pfu RAdLacZ, or saline and treated with con A or
vehicle 24 hours after adenovirus injection. Serum transaminases (GPT)
were measured 6 hours after administration of con A.
HEPATOLOGY, Vol. 37, No. 2, 2003 LASARTE ET AL. 463shown in Fig. 1C, RAdCE1 or RAdLacZ given alone (at
the highest dose used in this study) did not cause signiﬁ-
cant liver damage per se.
Intravenous administration of con A to BALB/c mice
inducessevereliverinjurywithin6to8hours.21Tostudy
the effect of HCV structural proteins on con A–induced
liver injury, groups of 6-week-old female BALB/c mice
were injected intravenously with different doses of
RAdCE1 (107,1 0 8, and 109 pfu), 109 pfu RAdLacZ, or
salineand24hourslaterreceivedanintravenousinjection
of con A or vehicle. Parameters of liver damage were de-
termined 6 hours after exposure to con A or vehicle.
WefoundthatintravenousinjectionofRAdCE1atthe
doses of 109 and 108 pfu (but not at 107 pfu) markedly
reduced the increase in alanine aminotransferase levels
induced by administration of con A, whereas 109 pfu
RAdLacZ was ineffective (Fig. 1C). Similarly, serum bil-
irubin levels (concentration in normal mice, 0.16  0.13
mol/L) increased after administration of con A to
0.86  0.14 and 0.82  0.17 mol/L in mice pretreated
with109pfuRAdLacZorsaline,respectively,butshowed
values of 0.31  0.06 mol/L after con A challenge in
those pretreated with 109 pfu RAdCE1 (P  .05 com-
pared with RAdLacZ or saline).
Because administration of con A causes apoptosis of
hepatocytes in a dose-dependent manner,21,22 we ana-
lyzed the number of TUNEL-positive nuclei in the dif-
ferent groups of animals. In mice treated with RAdLacZ
orsaline,conAcausedhepatocyteapoptosiswithapatchy
distribution within the liver parenchyma with areas with
abundant TUNEL-positive nuclei (Fig. 2B and C) and
areas with a lower rate of apoptosis. In sharp contrast,
mice receiving 109 pfu RAdCE1 were fully protected
against apoptosis of hepatocytes (Fig. 2A) in such a man-
nerthatliversectionsweresimilartothoseofanimalsthat
did not receive con A (Fig. 2D-F).
To determine the relationship between hepatocyte ap-
optosis and HCV core expression, we performed double
staining for apoptosis (green ﬂuorescence) and HCV core
(red ﬂuorescence) in liver specimens from mice treated
with107pfuRAdCE1thatexhibitedfewtransducedliver
cells and a high rate of apoptosis after administration of
con A. We found that the presence of red ﬂuorescence
in the cytoplasm of hepatocytes completely excluded
TUNEL positivity in the cell nucleus in every instance
(representativeexamplesareshowninFig.2G-J),indicat-
ing protection of cells expressing HCV core against cyto-
kine-induced apoptosis.
Administration of con A is accompanied by increased
levels of several cytokines, with TNF- and IFN- the
main mediators of liver damage.23,24 We measured the
serumconcentrationofthese2cytokinesinconA–treated
mice previously injected with RAdCE1 (109 pfu), RAd-
LacZ (109 pfu), or saline, and no signiﬁcant differences
werefoundforeitherIFN-(5,998520,5,800248,
and 5,662  225 pg/mL, respectively, in the 3 groups of
mice) or TNF- (1,580  310, 1,220  550, and
1,210  280 pg/mL, respectively) among groups. These
results indicate that the protective effect of RAdCE1 is
not due to an inhibition in the production of cytokines
inducedbyconAbutrathertoaprotectionofhepatocytes
against cytokine-mediated cell death.
Fig. 2. Recombinant adenovirus RAdCE1 protects mice from apopto-
sis induced by administration of con A. Apoptosis was determined by
TUNEL in liver sections from con A–treated mice previously injected with
1  109 pfu RAdCE1, RAdLacZ, or saline (A, B, and C, respectively) and
from mice injected with 1  109 pfu RAdCE1, RAdLacZ, or saline that
received vehicle instead of con A (D, E, and F, respectively). Double
staining for apoptosis (G and J) (TUNEL reaction: green ﬂuorescence) and
for HCV core (H and I) (indirect immunostaining: red ﬂuorescence) in liver
sections from con A–treated mice previously injected with 1  107 pfu
RadCE1. (Original magniﬁcation: A-F, 400; G-J, 1,000.) G and H as
well as I and J correspond to the same ﬁelds under different light ﬁlters.
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Hepatitis Caused by Administration of TNF-/D-
Galactosamine. TNF-hasbeenshowntoplayacrucial
role in con A–induced hepatitis.22,23 Because challenge
with TNF- after administration of D-galactosamine in-
duces hepatocyte apoptosis in mice, we wanted to deter-
mine whether the cytoprotective effect of RAdCE1 also
extended to this form of liver injury. To this aim, TNF-
/D-galactosamine was administered, as indicated in Ma-
terials and Methods, to mice treated 24 hours before with
109 pfu RAdCE1, 109 pfu RAdLacZ, or saline. Similar to
what we observed in the con A model, RAdCE1 was able
to exert strong protection of liver cells against TNF-/D-
galactosamine injury both as estimated by the levels of
serum transaminases (Fig. 3A) and by the presence of
TUNEL-positive nuclei in liver biopsy specimens (Fig.
3B-E).
Transduction of the Liver With RAdCE1 Inhibits
Translocation of NF-B to the Nucleus and iNOS
Expression After con A Challenge. One of the down-
stream targets of TNF receptor is the transcription factor
NF-B. This factor is sequestered in the cytoplasm by
IB; on binding of TNF- to its receptor, IB is phos-
phorylated, ubiquitinated, and targeted to the protea-
some for degradation. Free NF-B then translocates to
the nucleus and binds to consensus elements within the
promoters of a variety of genes.25 To analyze the mecha-
nismsresponsiblefortheprotectionaffordedbyRAdCE1
against con A–induced hepatitis, we determined the
presence of nuclear NF-B in the livers of the different
experimental groups of mice. Thus, 6 hours after admin-
istration of con A, nuclear extracts from liver cells of ani-
mals treated with RAdCE1, RAdLacZ, or saline were
obtained and NF-B binding activity was assessed by
means of electrophoretic mobility shift assay. We found
thatthetranslocationofNF-Btonucleiwassigniﬁcantly
reduced in mice given RAdCE1 compared with those
receiving RAdLacZ or saline (Fig. 4). This ﬁnding indi-
cates that the expression of HCV structural genes in liver
cells causes a block in the signaling pathway of TNF-,
preventing nuclear translocation of NF-B.
IthasbeenshownthatiNOSisstronglyinduced4to8
hours after administration of con A and that this event is
critical for immune-mediated liver injury induced by con
A.26 It has also been shown that activation of NF-Bi s
essential for the expression of iNOS in hepatocytes.27,28
To gain insight into the mechanism of RAdCE1 protec-
tion against con A–induced hepatitis, we determined the
levels of iNOS 6 hours after con A challenge in livers of
micetreatedwithRAdCE1,RAdLacZ,orsaline.Western
blotanalysisshowedacompleteabsenceofiNOSinlivers
from animals that received RAdCE1, whereas detectable
levels were present in the livers of animals from the other
2 groups (Fig. 5).
Administration of RAdCE1 Reduces Macrophage
Inﬂammatory Protein 2, Monocyte Chemoattractant
Protein 1, and IP-10 Chemokine Expression and In-
hibits Leukocyte Inﬁltration in the Livers of Mice
That Received con A. The production of proinﬂamma-
tory cytokines, notably TNF-, during the ﬁrst hours
after con A challenge is followed by activation of tran-
scriptionfactorsandmediatorsthatinducetheexpression
of chemokines that attract leukocytes to the liver.29,30
These cells orchestrate an inﬂammatory response in the
liver parenchyma contributing to the enhancement of
Fig. 3. Recombinant adenovirus RAdCE1 protects mice from acute
severe hepatitis induced by administration of TNF- plus D-galac-
tosamine. Mice were injected intravenously with 1  109 pfu RAdCE1,
RAdLacZ, or saline 24 hours before administration of TNF-/D-galac-
tosamine. A group of untreated mice was used as negative control. Six
hours after administration of TNF-/D-galactosamine, (A) serum
transaminase levels and (B-E) liver cell apoptosis were measured.
Apoptosis was determined by TUNEL in liver sections from mice treated
with (B) RAdCE1, (C) RAdLacZ, or (D) saline before administration of
TNF-/D-galactosamine or from (E) untreated mice as negative control.
(Original magniﬁcation 200.)
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assay, we explored the expression of chemokines 6 hours
after administration of con A in the livers of animals
treated with RAdCE1, RAdLacZ, or saline. We found
that administration of con A resulted in the induction of
several chemokines, with macrophage inﬂammatory pro-
tein 2 (MIP-2), monocyte chemoattractant protein 1
(MCP-1), TCA-3, and IP-10 the most clearly overex-
pressed(Fig.6).Interestingly,weobservedthattreatment
with RAdCE1 inﬂuenced the expression of several che-
mokines in liver tissue. In particular, MIP-2 was reduced
more than 15-fold and MCP-1 and IP-10 were decreased
more than 3-fold in RAdCE1-treated mice compared
with the control groups. No relevant changes were ob-
served in the expression of TCA-3, Lnt, RANTES,
Eotaxin, MIP-1, or MIP-1.
Todeterminewhethertheobservedchangesinchemo-
kine expression had a reﬂection in the hepatic inﬂamma-
torycellinﬁltrate,wekilledanimalsinthe3experimental
groups 24 hours after administration of con A and liver
specimens were stained with hematoxylin-eosin (Fig. 7).
We found that while animals from groups treated with
RAdLacZ or saline exhibited apoptotic bodies, necrotic
areas, and leukocyte inﬁltration in portal tracts (Fig. 7B
and C), there was absence of portal leukocyte inﬁltration
in those treated with RAdCE1 (Fig. 7A) and a liver his-
tology similar to that found in mice that did not receive
con A (Fig. 7F). Administration of 1  109 pfu RadCE1
or RAdLacZ in the absence of treatment with con A did
not induce detectable leukocyte inﬁltration (Fig. 7D and
E, respectively).
Discussion
There is no simple small animal model of HCV infec-
tion that could be used to analyze in vivo the inﬂuence of
HCV structural proteins on the response of hepatocytes
to proinﬂammatory cytokines. To investigate this point,
wehaveusedconAorTNF-/D-galactosaminechallenge
in mice whose livers had been transduced with control
adenovirus or with an adenovirus encoding HCV core
and E1. In animals treated with 109 pfu RAdCE1, more
than60%oflivercellsexpressedthetransgene.Inpatients
with chronic HCV infection, HCV proteins can be de-
tected immunohistochemically in 15% to 75% of hepa-
Fig. 4. Recombinant adenovirus RAdCE1 reduces NF-B nuclear
translocation induced by administration of con A. Mice were injected
intravenously with 1  109 pfu RAdCE1, RAdLacZ, or saline 24 hours
before administration of con A. A group of mice treated with saline was
used as negative control. Six hours after administration of con A, liver
nuclear extracts were obtained and NF-B binding activity was deter-
mined by electrophoretic mobility shift assay using an oligonucleotide
containing the B consensus site labeled with [-32P]–adenosine
triphosphate. Separation of the complexes was performed in a 5%
nondenaturing polyacrylamide gel electrophoresis and visualized by over-
night exposition to x-ray ﬁlm.
Fig. 5. Recombinant adenovirus RAdCE1 inhibits iNOS protein expres-
sion in the livers of con A–treated mice. Mice were injected with 1  109
pfu RAdCE1, RAdLacZ, or saline 24 hours before administration of con A.
Six hours after injection of con A, 25 g of liver protein extract was
separated by electrophoresis on an 8% sodium dodecyl sulfate acryl-
amide gel. con A–induced iNOS expression was detected by western
blotting. Actin was used as internal control. Liver protein extracts from
nontreated mice served as negative control.
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the immunopathobiological changes of chronic hepatitis
C, it is a useful approach to investigate the effect of HCV
proteins expressed inside liver cells on cytokine-induced
hepatocellular damage.
Inthisstudy,weshowthatmicetreatedwithRAdCE1
exhibit a marked suppression in the increase in serum
transaminase and bilirubin levels as well as in the rate of
apoptotic cells in the liver after con A challenge. con A is
a T-cell mitogenic plant lectin that causes severe hepatitis
within 4 to 8 hours.21 Administration of con A is accom-
panied by increased levels of several cytokines, including
interleukin2,TNF-,IFN-,interleukin6,granulocyte-
macrophage colony–stimulating factor, and interleukin
1.21,23,24 Among these cytokines, TNF- may play a ma-
jor role in mediating apoptosis of hepatocytes.22,23,32 In
our study, treatment with RAdCE1 did not reduce the
levels of TNF- and IFN- after con A challenge, indi-
cating that the observed protective effect was not due to a
decrease in the release of cytokines but rather to an en-
hanced resistance to cytokine-induced apoptosis of liver
cells.Thisconceptisalsosupportedbytheﬁndingthat,in
animals treated with 107 pfu RAdCE1 showing a low
number of transduced cells and a high rate of apoptosis
after con A challenge, the expression of core by hepato-
cyteswasalwaysfoundtoexcludethepresenceofTUNEL
positivity at the single-cell level.
Ligation of TNF- receptor 1 (TNFR1) by TNF-
activates diverse intracellular signaling cascades that di-
verge at the inner cell membrane. TRADD, which binds
to the cytoplasmic domain of TNFR1, is important for
the activation of all of these pathways.33,34 During
TNFR1 activation, TRAF2 and RIP bind to TRADD,
initiating downstream events leading to nuclear translo-
cation of NF-B. The inhibition of NF-B translocation
and liver cell apoptosis in the con A hepatitis model after
Fig. 6. Recombinant adenovirus RAdCE1 abrogated MIP-2 and re-
duced MCP-1 and IP-10 chemokine messenger RNA expression in the
livers of mice treated with con A. Groups of 4 mice were injected
intravenously with 1  109 pfu RAdCE1, RAdLacZ, or saline 24 hours
before administration of con A. A group of untreated mice was used as
negative control. Six hours after administration of con A, liver RNA was
extracted and messenger RNA for different chemokines was quantiﬁed by
using (A) mCK-5b multiprobe ribonuclease protection assay or (B)
speciﬁc probes for IP-10 and glyceraldehyde-3-phosphate dehydroge-
nase.
Fig. 7. Recombinant adenovirus
RAdCE1 reduces leukocyte inﬁltra-
tion in the liver after administration
of con A. Mice were injected intra-
venously with (A and D) 1  109
pfu RAdCE1, (B and E) RAdLacZ, or
(C and F) saline 24 hours before
administration of (A-C) con A or
(D-F) vehicle. Twenty-four hours af-
ter administration of con A, liver sec-
tions were ﬁxed in formol, included
in parafﬁn, and stained with hema-
toxylin-eosin. (Original magniﬁcation
200.)
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disruption of TNF- signaling in hepatocytes because
RAdCE1 also inhibits TNF-/D-galactosamine–induced
acute liver injury. This view is reinforced by recent data
showing that HCV core protein can bind to the cytoplas-
mic domain of the TNFR1, forming a ternary complex
with TNFR1 and TRADD.35
In con A–induced hepatitis, nuclear translocation of
NF-Bisessentialforgenerationofproinﬂammatoryme-
diators and chemokines. In particular, NF-B activation
isnecessaryforhepatocellularexpressionofiNOS,28akey
enzymeinmediatingliverdamageinconA–inducedhep-
atitis.26 In fact, serum transaminase levels and TUNEL-
positivenucleiaremarkedlyreducedafterconAchallenge
iniNOSknockoutmicecomparedwithwild-typemice.26
On the other hand, both NO and nuclear NF-B are
necessary for the induction of chemokine production.
Thus MIP-2, MCP-1, and IP-10 are regulated by NF-
B36-38andNOisnecessaryfortheexpressionofMIP-239
and MCP-1.40 In our study, we found that while control
miceshowedmarkednucleartranslocationofNF-Band
production of iNOS in the liver after con A challenge,
animals pretreated with RAdCE1 showed inhibition of
NF-B nuclear translocation and iNOS expression. This
last group of mice also manifested reduced expression of
chemokines MIP-2, MCP-1, and IP-10, which are regu-
lated by NF-B and/or NO. Therefore, it seems that
blockade of NF-B activation, decreased production of
iNOS, and reduced chemokine expression in RAdCE1-
treated mice are mechanistically connected events. How-
ever, although inhibition of iNOS production seems
important in RAdCE1-mediated protection against con
A challenge, this adenovirus seems to lessen cytokine-
mediated liver injury by blocking other TNF- death
signals because it also protects against TNF-/D-galac-
tosamine, a model of liver injury that causes hepatocellu-
lar damage in the iNOS knockout mice.26
MCP-1 exhibits a chemoattractive activity for mono-
cytes and T lymphocytes and triggers the adhesion of
rolling monocytes to sites of inﬂammation. Similarly,
IP-10 is a selective chemoattractant for activated T lym-
phocytes(reviewedbyBaggiolinietal.41).MIP-2isache-
moattractant for neutrophils42 and dendritic cells.43 The
inhibition in the expression of chemokines, together with
the inhibitory effect on hepatocyte apoptosis, may ac-
count for the lack of con A–induced inﬂammatory inﬁl-
trate in RAdCE1-treated livers. It also seems possible that
the capacity of HCV core and E1 proteins to reduce the
production of chemokines can interfere with the activa-
tion of antiviral immune responses, thereby suggesting a
new mechanism by which HCV establishes a persistent
infection.
TNF-, along with other Th1 cytokines, is up-regu-
lated in the liver of patients with chronic hepatitis C.6,7,44
These cytokines have potent proapoptotic effects and
could facilitate the elimination of infected liver cells. In
addition, cytokines such as TNF- can have a direct an-
tiviraleffectbyanoncytolyticmechanism.45Itisnotclear
how HCV can replicate actively and continuously in this
adverse inﬂammatory environment. Our observations are
relevant in this respect because they show that intracellu-
larexpressionofHCVstructuralproteinsmayconferpro-
tectionagainstcytokine-inducedcytotoxicity.Thisability
of HCV core may represent a fundamental mechanism of
chronicity of HCV infection because it provides a selec-
tive advantage for HCV replication, allowing for evasion
of host antiviral defenses. Our data also point to the idea
that, because HCV-infected hepatocytes have higher re-
sistance to apoptosis than noninfected cells, the increase
in serum transaminase levels and the histologic signs of
hepatocellularinjuryinchronichepatitisCwouldmainly
reﬂect the bystander and nonspeciﬁc damage of nonin-
fected cells in the liver inﬂammatory milieu.46,47 In this
context,itisimportanttoconsiderthatTNF-isapotent
inducer of the chemokine IP-10 in hepatocytes.48 This
chemokine selectively attracts activated liver inﬁltrating
lymphocytes to cells that are producing the chemotactic
factor.29 In chronic hepatitis C, there is a marked up-
regulation of IP-10,49 which is an important player in the
maintenance of the inﬂammatory reaction in the liver.
OurdatashowingthatHCVcore/E1blocksthecytokine-
driven expression of IP-10 suggest that, in chronic hepa-
titis C, activated liver-inﬁltrating lymphocytes will be
mainly attracted to noninfected hepatocytes with result-
ing diversion from infected cells and increased bystander
damage to noninfected hepatocytes. Thus, our ﬁndings
might favor the idea that, in chronic HCV infection, per-
sistent liver inﬂammation might result in progression of
liver damage without affecting viral replication.
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